10-Q: ENDRA Life Sciences Narrows Losses, Pivots to Crypto Amid Going Concern

ENDRA Life Sciences reported reduced net losses and operating expenses for Q3 2025, while initiating a Digital Asset Treasury strategy and addressing Nasdaq listing compliance.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $3,858,201 from $7,358,943 in the prior year.
• Operating loss also improved, decreasing to $4,141,075 for the nine months ended September 30, 2025, from $6,520,408 in the same period last year.
• Research and development expenses decreased by 47% to $1,341,859, as the company completed initial TAEUS product development and shifted focus to clinical trials and commercialization.
• Sales and marketing expenses fell by 62% to $183,110, primarily due to restructuring efforts in Q2 2024.
• General and administrative expenses decreased by 25% to $2,616,106.
• The company adopted a Digital Asset Treasury (DAT) strategy in 2025, allocating its principal treasury reserve to cryptocurrency, starting with HYPE tokens.
• On October 23, 2025, ENDRA purchased 78,863.1 HYPE tokens with an estimated value of approximately $3,000,000.
• Cash balance as of September 30, 2025, was $794,036, down from $3,229,480 at December 31, 2024.
• Stockholders' equity as of September 30, 2025, was $171,380, a significant decrease from $2,560,366 at December 31, 2024.
• A material weakness in internal control over financial reporting was identified due to insufficient accounting personnel resources for segregation of duties.
• The company received an extension from Nasdaq until November 24, 2025, to regain compliance with the $2.5 million Stockholders Equity Requirement, which it believes it has achieved through a recent private placement.

Sentiment

Score: 4

Explanation: While the company showed improved financial performance with reduced net and operating losses, and successfully raised capital, its cash position remains very low, and it continues to operate under a 'going concern' warning. The pivot to a Digital Asset Treasury strategy introduces significant, unquantifiable risks and regulatory uncertainties, making the company's future highly speculative despite the capital infusion.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by 47.5% to $3,858,201 compared to $7,358,943 in the prior year.
• Operating loss for the nine months ended September 30, 2025, decreased by 36.5% to $4,141,075 compared to $6,520,408 in the prior year.
• Research and development expenses decreased by 47% to $1,341,859, indicating a shift from initial development to clinical trials and commercialization.
• Sales and marketing expenses decreased by 62% to $183,110, reflecting cost reduction efforts.
• General and administrative expenses decreased by 25% to $2,616,106, contributing to reduced overall operating expenses.
• The company successfully closed a private placement offering on October 15, 2025, raising approximately $4.9 million in gross proceeds, which is expected to help regain Nasdaq Stockholders Equity compliance.
• The company secured a new At-The-Market (ATM) Issuance Sales Agreement for up to $1,750,000, providing an additional potential source of capital.

Negatives

• The company has an accumulated deficit of $107,296,300 as of September 30, 2025.
• Cash balance significantly decreased to $794,036 as of September 30, 2025, from $3,229,480 at December 31, 2024.
• Stockholders' equity drastically fell to $171,380 as of September 30, 2025, from $2,560,366 at December 31, 2024, indicating a precarious financial position.
• The company has not generated any revenue from its TAEUS technology as of September 30, 2025.
• Management identified a material weakness in internal control over financial reporting due to insufficient accounting personnel resources for segregation of duties.
• The company's ability to continue as a going concern is dependent on obtaining adequate capital, raising substantial doubt about its future operations.
• The majority of net proceeds from the October 2025 private placement are intended for the Digital Asset Treasury strategy, with only $750,000 allocated to the TAEUS program.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to limited commercial experience, cumulative net loss, and need for additional financing.
• Risk that certain cryptocurrencies may be classified as securities, subjecting the company to additional regulation and potentially requiring registration as an investment company under the 1940 Act.
• The emergence or growth of other digital assets (e.g., stablecoins, CBDCs) could negatively impact the price of cryptocurrencies held by the company.
• If deemed an investment company under the 1940 Act, applicable restrictions would likely make it impractical to continue segments of the business as currently contemplated.
• Regulatory developments related to crypto assets and crypto asset markets could adversely affect the business, financial condition, and results of operations.
• Changes in the accounting treatment of cryptocurrency holdings (e.g., ASU 2023-08) could have significant accounting impacts, increasing volatility of financial results.
• Management's reliance on an asset manager for the cryptocurrency strategy may not yield desired returns, and the highly volatile nature of cryptocurrency prices could depress asset valuations.
• Digital asset trading platforms, especially for small-cap cryptocurrencies, are relatively new, often unregulated, and susceptible to fraud, market manipulation, security breaches, and operational failures.
• The company's custodially-held cryptocurrencies may become part of the custodian's insolvency estate if a custodian enters bankruptcy, potentially leading to loss of assets.
• Cryptocurrencies do not pay interest or dividends, and generating cash from holdings depends on sales or income-generating strategies, which may not be successful.
• The company is not subject to legal and regulatory obligations that apply to investment companies (e.g., mutual funds, ETFs) or investment advisers, giving the board broad discretion over investment policies.
• Security breaches, cyberattacks, loss of private keys, or other compromises to cryptocurrency blockchains could result in partial or total loss of cryptocurrency and materially adversely affect financial condition.
• The company's stock is subject to minimum requirements to remain listed on the Nasdaq Capital Market, including a minimum bid price and stockholders' equity requirement, and may be delisted if compliance is not maintained.
• Inability to obtain sufficient additional financing on acceptable terms could require delays, reductions, or elimination of research/development or commercialization efforts, or even cessation of business operations.

Future Outlook

The company plans to continue advancing the engineering design and development of its TAEUS technology, acquire parts and build finished goods inventory, and complete regulatory filings for marketing approval of its NAFLD TAEUS application in the United States, including clinical studies for FDA de novo application. It intends to hire a small internal marketing team post-FDA approval and expand marketing efforts. The company also plans to expand its Digital Asset Treasury strategy, accumulating a long-term position in one to five decentralized finance digital assets. Significant expenses and operating losses are expected for the foreseeable future, requiring additional capital through equity offerings, debt financings, or collaborations.

Management Comments

• Management believes all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included in the unaudited condensed consolidated financial statements.
• Management's plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing, though no assurances of success can be provided.
• Management intends to implement measures to remediate the material weakness in internal control over financial reporting, including adding accounting personnel or outside consultants and developing adequate written accounting policies and procedures, contingent on obtaining additional funding.

Industry Context

ENDRA Life Sciences operates in the medical device sector, specifically developing a thermo-acoustic enhanced ultrasound (TAEUS) technology for liver fat measurement, targeting metabolic disease detection and GLP-1 drug management. This places it in a competitive landscape with other imaging technologies (CT, MRI) and emerging GLP-1 therapies. The company's recent pivot to a Digital Asset Treasury (DAT) strategy, holding decentralized finance digital assets like HYPE, represents a significant and highly unconventional move for a biotech firm. This strategy introduces the company to the volatile and evolving cryptocurrency market, which is subject to unique regulatory, technical, and market risks, diverging sharply from its core medical device development.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The company uses IS Bookkeeping & Payroll, a division of Impact Solve, LLC, an accounting and CFO service firm. The company's CFO works in a part-time capacity through Impact Solutions.
• For the three months ended September 30, 2025, services from Impact Solutions totaled $45,548.
• For the nine months ended September 30, 2025, services from Impact Solutions totaled $126,566.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity offerings. The new Digital Asset Treasury strategy introduces high volatility and regulatory uncertainty, potentially impacting share price. Nasdaq listing compliance issues also pose a risk to liquidity and investor confidence.
• **Employees:** Continued operational challenges and the 'going concern' warning create job insecurity. However, the shift in R&D focus and potential commercialization of TAEUS, along with the new DAT strategy, could offer new opportunities if successful.
• **Customers (potential):** The development and eventual commercialization of the TAEUS medical device could provide new solutions for metabolic disease detection and management, but regulatory approvals are still pending.
• **Creditors:** The 'going concern' warning and low cash balance indicate elevated risk. The company's ability to meet obligations is highly dependent on future capital raises and the success of its new strategies.
• **Suppliers:** May face payment delays or reduced orders if the company's financial condition deteriorates further or if capital raising efforts are unsuccessful.

Next Steps

• Advance the engineering design and development of the TAEUS technology.
• Acquire parts and build finished goods inventory of the TAEUS FLIP system.
• Complete regulatory filings for marketing approval of the NAFLD TAEUS application in the United States, including clinical studies for de novo FDA application.
• Seek to hire a small internal marketing team to engage and support channel partners and clinical customers for the NAFLD TAEUS application.
• Expand marketing of the NAFLD TAEUS application.
• Advance development of other TAEUS applications.
• Add operational, financial, and management information systems and personnel.
• Monitor ongoing developments in the regulatory environment around cryptocurrencies and potentially modify or expand the DAT strategy.
• Implement measures to remediate the material weakness in internal control over financial reporting, including adding accounting personnel or outside consultants and developing written policies.

Key Dates

Recommendation

While ENDRA Life Sciences has shown an improvement in reducing its net and operating losses year-over-year, and has successfully raised capital through a private placement and established a new ATM facility, the company remains in a highly precarious financial position with a 'going concern' warning and very low stockholders' equity. The strategic pivot to a Digital Asset Treasury, investing in volatile cryptocurrencies like HYPE, introduces a new layer of significant, unquantifiable risk and regulatory uncertainty that fundamentally changes the company's risk profile. For existing investors, holding may be warranted to observe the execution of the DAT strategy and progress towards TAEUS commercialization, given the recent capital infusion. However, for new investors, the high speculative nature, combined with the ongoing financial challenges and the material weakness in internal controls, suggests extreme caution. The stock is highly speculative, and a 'hold' recommendation reflects the need for more clarity on the long-term viability of both the medical device business and the new, high-risk crypto treasury strategy.

Keywords

ENDRA Life Sciences, TAEUS, Medical Device, Liver Fat Measurement, Digital Asset Treasury, Cryptocurrency, HYPE Token, Nasdaq Compliance, Going Concern, SEC Filing, 10-Q, Biotech, Financial Results, Capital Raise, Risk Factors, Corporate Governance, GLP-1